Therapeutic Approaches to the Challenge of Neuronal Ceroid Lipofuscinoses
Open accessThe DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Abstract
The Neuronal Ceroid Lipofuscinoses (NCLs) are lysosomal storage diseases (LSDs) affecting the central nervous system (CNS), with generally with recessive inheritance. They are characterized by pathological lipofuscin-like material accumulating in cells. The clinical phenotypes at all onset ages show progressive loss of vision, decreasing cognitive and motor skills, epileptic seizures and premature death, with dementia without visual loss prominent in the rarer adult forms. Eight causal genes, CLN10/CTSD, CLN1/PPT1, CLN2/TPP1, CLN3, CLN5, CLN6, CLN7/MFSD8, CLN8, with more than 269 mutations and 49 polymorphisms (http://www.ucl.ac.uk/ncl) have been described. Other NCL genes are hypothesized, including CLN4 and CLN9; CLCN6, CLCN7 and possibly SGSH are under study. Some therapeutic strategies applied to other LSDs with significant systemic involvement would not be effective in NCLs due to the necessity of passing the blood brain barrier to prevent the neurodegeneration, repair or restore the CNS functionality. There are therapies for the NCLs currently at preclinical stages and under phase 1 trials to establish safety in affected children. These approaches involve enzyme replacement, gene therapy, neural stem cell replacement, immune therapy and other pharmacological approaches. In the next decade, progress in the understanding of the natural history and the biochemical and molecular cascade of events relevant to the pathogenesis of these diseases in humans and animal models will be required to achieve significant therapeutic advances. Keywords: Enzyme replacement, gene, immune, lysosomal storage diseases, Neuronal ceroid lipofuscinoses, pharmacological, stem cell, therapies, progressive loss of vision, decreasing cognitive and motor skills, dementia, blood brain barrier, neural stem cell replacement, molecular cascade of events, autofluorescence
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hematopoietic Stem Cell Gene Therapy with a Lentiviral Vector in X-Linked Adrenoleukodystrophy
Cartier, N., Hacein-Bey-Abina, S., Bartholomae, C. C., Veres, G., Schmidt, M., Kutschera, I., Vidaud, M., Abel, U., Dal-Cortivo, L., Caccavelli, L., et al. (2009) · Science · doi:10.1126/science.1171242 · Cited by 1,508
Saijo, K., Winner, B., Carson, C. T., Collier, J. G., Boyer, L., Rosenfeld, M. G., Gage, F. H., & Glass, C. K. (2009) · Cell · doi:10.1016/j.cell.2009.01.038 · Cited by 957 · cited 1×
“The response is the secretion of inflammatory mediators such as TNF-α and IL-1β that can act on astrocytes to induce the secondary inflammatory responses [173].”
BackgroundER stress and neurodegenerative diseases
Lindholm, D., Wootz, H., & Korhonen, L. (2006) · Cell Death & Differentiation · doi:10.1038/sj.cdd.4401778 · Cited by 882 · cited 1×
“The authors found no similar evidence than in human skin fibroblasts from GM1, CLN1, other neurodegenerative LSDs, Parkinson’s and Alzheimer’s diseases [130].”
Worgall, S., Sondhi, D., Hackett, N. R., Kosofsky, B., Kekatpure, M. V., Neyzi, N., Dyke, J. P., Ballon, D., Heier, L., Greenwald, B. M., et al. (2008) · Human Gene Therapy · doi:10.1089/hum.2008.022 · Cited by 402 · cited 3×
“ClinicalTrials.gov number NCT00337636); 2) Observational Study on Genotype-Phenotype correlations of LINCL (NCT00151268) [61,62]; 3) the currently recruiting participants Safety Study of a Gene Transfer Vector AAV2CUhCLN2 (NCT00151216) [62]; 4) the phase II Study on a Combination Therapy with Cystagon and N-Acetylcyst…”
BackgroundPeters, C., Charnas, L. R., Tan, Y., Ziegler, R. S., Shapiro, E. G., DeFor, T., Grewal, S. S., Orchard, P. J., Abel, S. L., Goldman, A. I., et al. (2004) · Blood · doi:10.1182/blood-2003-10-3402 · Cited by 374
Wang, J.-Y., Wen, L. L., Huang, Y.-N., Chen, Y.-T., & Ku, M.-C. (2006) · Current Pharmaceutical Design · doi:10.2174/138161206778343109 · Cited by 250
Neufeld, E. F., & Fratantoni, J. C. (1970) · Science · doi:10.1126/science.169.3941.141 · Cited by 215 · cited 16×
“Clinical trials in other LSDs using similar ERT approaches were also successful, including Mucopolysaccharidosis I, II and VI [85-90].”
BackgroundInfluentialNatowicz, M. R., Chi, M. M., Lowry, O. H., & Sly, W. S. (1979) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.76.9.4322 · Cited by 213 · cited 16×
“Clinical trials in other LSDs using similar ERT approaches were also successful, including Mucopolysaccharidosis I, II and VI [85-90].”
BackgroundInfluentialYou say lipofuscin, we say ceroid: Defining autofluorescent storage material
Seehafer, S. S., & Pearce, D. A. (2006) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2005.12.006 · Cited by 212
Sondhi, D., Hackett, N. R., Peterson, D. A., Stratton, J., Baad, M., Travis, K. M., Wilson, J. M., & Crystal, R. G. (2007) · Molecular Therapy · doi:10.1038/sj.mt.6300049 · Cited by 170 · cited 17×
“Neurons are particularly sensitive to the lysosomal accumulation of storage materials; individuals with CLN1 or CLN2 diseases show a generalized extensive and progressive neurodegeneration, eventually resulting in a vegetative state and premature death [55,101,109].”
BackgroundInfluentialAAV2-mediated ocular gene therapy for infantile neuronal ceroid lipofuscinosis
Griffey, M., Macauley, S. L., Ogilvie, J. M., & Sands, M. S. (2005) · Molecular Therapy · doi:10.1016/j.ymthe.2005.04.018 · Cited by 115 · cited 25×
“Clinical trials in other LSDs using similar ERT approaches were also successful, including Mucopolysaccharidosis I, II and VI [85-90].”
BackgroundMethodInfluential
Cited by
Inflammatory Response in the CNS: Friend or Foe?
Sochocka, M., Diniz, B. S., & Leszek, J. (2017) · Molecular Neurobiology · doi:10.1007/s12035-016-0297-1 · Cited by 573
An Overview of the Role of Lipofuscin in Age-Related Neurodegeneration
Moreno-García, A., Kun, A., Calero, O., Medina, M., & Calero, M. (2018) · Frontiers in Neuroscience · doi:10.3389/fnins.2018.00464 · Cited by 372
“NCLs are a group of rare neurodegenerative disorders characterized by intracellular (and at a minor extent extracellular) accumulation of a fluorescent lipopigment called “ceroid lipofuscin” (Kohan et al., 2011).”
BackgroundThe Role of Cathepsin D in the Pathogenesis of Human Neurodegenerative Disorders
Vidoni, C., Follo, C., Savino, M., Melone, M. A. B., & Isidoro, C. (2016) · Medicinal Research Reviews · doi:10.1002/med.21394 · Cited by 164
Metadata
- Authors
- Kohan, R., A. Cismondi, I., M. Oller-Ramirez, A., Guelbert, N., Tapia Anzolini, V., Alonso, G., E. Mole, S., Dodelson de Kremer, R., & Noher de Halac, I.
- Venue
- Current Pharmaceutical Biotechnology
- Publisher
- Bentham Science Publishers Ltd.
- Published
- 2011-06-01
- Volume
- 12
- Issue
- 6
- Pages
- 867-883
- ISSN
- 1389-2010 (ISSN-L)
- OpenAlex
- W2143114059
- Cited by
- 61
- References
- 11
- FWCI
- 3.85
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.